Core Insights - The company reported a 49.08% year-on-year increase in R&D expenses for the first three quarters of 2025, focusing on new PEG integrated interferon mutant injection for hepatitis B treatment and γδT cell tumor immunotherapy clinical research [1][2] Group 1: R&D Investments - The primary investment is in the development of new PEG integrated interferon, which is expected to significantly improve the clinical cure rate for chronic hepatitis B through genetic testing [1] - The company has completed a large sample (940 cases) whole genome scan, establishing a seamless clinical research plan for II-III phase trials with clinical cure as the endpoint [1] Group 2: Tumor Immunotherapy - The company has conducted clinical observations on 36 cases of liver cancer, melanoma, and acute myeloid leukemia, demonstrating good safety for allogeneic γδT cells [2] - Acute myeloid leukemia has been identified as the core clinical development direction based on systematic analysis of preliminary clinical data [2] Group 3: Strategic Expansion - The company has strategically extended its recombinant protein technology platform into the field of recombinant human collagen, achieving breakthroughs in molecular structure and expression systems [2] - This new business segment is expected to complement existing serious medical operations while entering the consumer healthcare market [2] Group 4: Long-term Development - Through high-intensity R&D investments, the company is transforming its technological advantages into future market competitiveness, building a solid moat for sustainable long-term development [2] - The company is poised for continuous breakthroughs based on steady progress in its pipeline products and the gradual establishment of new business segments [2]
研发驱动构筑核心竞争力 三元基因持续将技术优势转化为市场竞争力